Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RLMD
Bullish
high confidence
Mentioned
$RLMD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLMDBullishHigh
01

Why it matters

The disclosed Phase 2 durability data and cash position could drive short-term price appreciation, while the upcoming IND submissions present future catalysts.

02

Market read

First-report earnings and trial data for a clinical-stage biotech, offering fresh material for traders.

03

What to watch

Potential regulatory delays for IND submission and competition from other NMIBC therapies.

Relevance 7/10Novelty 9/10Timing: after-hours release

Background

Relmada Therapeutics (Nasdaq: RLMD) released its Q3 2026 financial results and provided an update on its NDV-01 oncology program and sepranolone pipeline.

Company-level read

Ticker impact

$RLMDBullishHigh confidence
Context

Relmada Therapeutics filed its Q3 2026 earnings and disclosed Phase 2 durability data showing 86% of patients remained in complete response at 18 months.

Expected impact

likely upward pressure as investors price in durable responses and extended cash runway

Evidence & confidence

The trial results exceed expectations and the company has sufficient cash to fund operations through 2029, reducing near-term financing risk.

Market effects

Strengthens the oncology biotech sector by showing promising durability in NMIBC therapy.

Minimal regional impact; primarily U.S. biotech investors.

Limited to global biotech investors tracking NMIBC developments.

Counterpoint

The durability data set is small (23 patients) and may not translate to larger Phase 3 outcomes.

Key entities

  • Sergio Traversa

    CEO of Relmada Therapeutics, commented on IND timeline.

  • Bipin Dalmia

    Chief Business Officer, highlighted Phase 2 results.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

$WMTHighAI 8/10

Walmart Has Raised Its Dividend 53 Straight Years. I'd Buy It Before December and Never Sell.

Walmart (WMT) reported better-than-expected sales and profits, raised its full-year forecast, and announced 53 consecutive years of dividend increases. Despite this, its stock fell 2% in early trading. The company's omnichannel model, advertising business, and AI shopping assistant contributed to its growth, while rising diesel prices and slowing same-store sales growth pose challenges. Walmart's dividend is payable to shareholders of record on December 11.